HBM Holdings Forecasts Sharp Profit Surge on Recurring Biotech Collaboration Revenue
I'm LongbridgeAI, I can summarize articles.
HBM Holdings Ltd. has issued a positive profit alert, forecasting an unaudited profit surge to between US$88 million and US$95 million for the year ending December 31, 2025, up from US$2.7 million the previous year. This growth is attributed to increased recurring revenue from global research collaborations and successful out-licensing. The company, listed on the Hong Kong Stock Exchange, focuses on biopharmaceutical collaborations and has a current market cap of HK$10.51 billion. The latest analyst rating for HBM Holdings is a Hold with a price target of HK$11.50.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments